Gatifloxacin Phase IV surveillance trial (TeqCES Study) utilizing 5,000 primary care physician practices: Report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
Gatifloxacin Phase IV surveillance trial (TeqCES Study) utilizing 5,000 primary care physician practices: Report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections. by Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 44 (1): 77-84
